vTv Therapeutics (NASDAQ:VTVT) Raised to Hold at Zacks Research

Key Points

• Zacks Research upgraded vTv Therapeutics to “Hold” from “Strong Sell,” while analyst sentiment overall remains “Moderate Buy,” with a consensus price target of $55.83.
• Shares opened at $32.79, compared with a 52-week range of $18.77 to $44.00; the company has a market capitalization of approximately $129.2 million.
• vTv Therapeutics reported a quarterly loss of $1.05 per share, missing the $0.97 consensus estimate, and analysts expect a full-year loss of $2.35 per share.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) was upgraded by Zacks Research from a "strong sell" rating to a "hold" rating in a research report issued on Monday, Zacks reports.

A number of other analysts also recently commented on VTVT. HC Wainwright dropped their price objective on vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating for the company in a report on Thursday, August 6th. Rodman & Renshaw started coverage on vTv Therapeutics in a report on Tuesday, June 30th. They issued a "buy" rating and a $67.00 target price on the stock. BTIG Research boosted their price target on vTv Therapeutics from $49.00 to $57.00 and gave the company a "buy" rating in a research report on Thursday, July 16th. Wall Street Zen lowered vTv Therapeutics from a "buy" rating to a "sell" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings downgraded vTv Therapeutics from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $55.83.

vTv Therapeutics Stock Performance

VTVT opened at $32.79 on Monday. vTv Therapeutics has a 1 year low of $18.77 and a 1 year high of $44.00. The company's 50 day simple moving average is $32.86 and its 200 day simple moving average is $34.51. The stock has a market capitalization of $129.19 million, a PE ratio of -30.93 and a beta of 0.29.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08). As a group, sell-side analysts expect that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On vTv Therapeutics

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after acquiring an additional 12,896 shares in the last quarter. 683 Capital Management LLC purchased a new stake in shares of vTv Therapeutics during the fourth quarter valued at approximately $731,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of vTv Therapeutics during the fourth quarter valued at approximately $221,000. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.